You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News items for the week of Sept. 28, 2020
The investment bank also raised its price target for the company to $15, based on PacBio's strategic plan to commercialize its long-read Sequel II system.
The method uses heat for extraction, which the company said will improve test turnaround time and reduce reliance on nucleic acid extraction reagents.
Tempus' test is a modified version of Thermo Fisher Scientific's Applied Biosystems TaqPath COVID-19 Combo Kit, which previously received EUA from the FDA.
The analysis further discovered that endemic cholera strains in Argentina were more diverse, a finding that could inform outbreak control efforts.
The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all fell in September.
Researchers found complex "rigma," "pyrgo," and "tyfona" structural variant classes by applying their new algorithm to thousands of cancer genomes.
With targeted, exome, and whole-genome sequencing data, investigators saw recurrent driver mutations and heterogeneous mutational signatures in seemingly normal bladders.
The two grants awarded will support DiamiR's development of microRNA diagnostics for mild cognitive impairment, Alzheimer's disease, and Rett syndrome.
CareDx hopes the final LCD for AlloSure Heart will lead to an approval of HeartCare, a combination of AlloSure Heart and AlloMap Heart.
The Swiss-American bioinformatics company has now raised more than $250 million and seeks to further expand expand deeper in the US and Asian markets.
Genuity Science, formerly known as WuXi NextCode, will receive a combination of upfront, development milestone, and product royalty payments under the deal.
The firm will use the funding from Keystone Capital Partners to advance its Cancer Differentiation Analysis technology to offer early detection screening and testing of 26 cancers.
Quidel's preliminary earnings more than doubled over the prior quarter on increasing SARS-CoV-2 test sales.
Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.
The tests are designed to detect viral nucleic acid in various respiratory specimens including nasal swabs, nasal aspirate, and bronchoalveolar lavage.
The two new grants add to a $1.5 million Phase II SBIR grant the company received from the National Institute of General Medical Sciences last year.
A gene cluster inherited by modern humans from Neanderthals was recently identified as a risk locus for respiratory failure following SARS-CoV-2 infection.
The researchers identified a strain of the bacterium Paenibacillus thiaminolyticus as well as cytomegalovirus among samples from infants with the condition.
The RT-PCR-based test, which runs on Becton Dickinson's BD Max system, simultaneously detects SARS-CoV-2, influenza A and B, and respiratory syncytial virus.
Called the Integrated Proteomics Pipeline, the platform offers search engine capabilities that will enable better use of collision cross section data.
The assay will include a multiplexed panel of established and emerging biomarkers and will be the first RNA-based assay on the Idylla platform using FFPE samples.
The firm noted that this is the first EUA for saline oral rinse collection used for SARS-CoV-2 testing, adding to its other approved collection methods.
The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.
The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.
The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.
In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.